A Review on Current Treatment of Multiple Sclerosis Disease

  • Trupti C. Shinde PRMSS Anuradha College of Pharmacy, Chikhli, Dist- Buldhana (M.S) India -443201
  • Snehal M. Wagh PRMSS Anuradha College of Pharmacy, Chikhli, Dist-Buldhana (MS) India 443201
  • Kaustubh B. Solanke PRMSS Anuradha College of Pharmacy, Chikhli, Dist-Buldhana (MS) India 443201
  • P. N. Folane PRMSS Anuradha College of Pharmacy, Chikhli, Dist-Buldhana (MS) India 443201

Abstract

Multiple sclerosis is a chronic inflammatory disease of the CNS characterized by the demyelination and axonal loss. The incidence of the MS is increasing worldwide. The underlying cause of MS and mechanisms behind this increase remain opaque, although complex gene, environmental interactions almost certainly play a significant role. The epidemiology of MS indicates the low serum level serum level of vitamin D, smoking and childhood obesity are likely to play a role in disease development. Diagnostic criteria have been adapted to facilitate earlier diagnosis with increased sensitivity and specificity.


 

Keywords: Multiple Sclerosis, Relapses, Lesions, diagnosis,

Downloads

Download data is not yet available.

Author Biographies

Trupti C. Shinde, PRMSS Anuradha College of Pharmacy, Chikhli, Dist- Buldhana (M.S) India -443201

PRMSS Anuradha College of Pharmacy, Chikhli, Dist- Buldhana (M.S) India -443201

Snehal M. Wagh, PRMSS Anuradha College of Pharmacy, Chikhli, Dist-Buldhana (MS) India 443201

PRMSS Anuradha College of Pharmacy, Chikhli, Dist-Buldhana (MS) India 443201

Kaustubh B. Solanke, PRMSS Anuradha College of Pharmacy, Chikhli, Dist-Buldhana (MS) India 443201

PRMSS Anuradha College of Pharmacy, Chikhli, Dist-Buldhana (MS) India 443201

P. N. Folane, PRMSS Anuradha College of Pharmacy, Chikhli, Dist-Buldhana (MS) India 443201

PRMSS Anuradha College of Pharmacy, Chikhli, Dist-Buldhana (MS) India 443201

References

1. Dobson R, Giovannoni G. Multiple sclerosis- a review. Eur J Neurol. 2019; 26(1):27-40.
2. Koblet G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. MultScler. 2007; 23:1123-1136.
3. Daniel S. Reich et al. Multiple Sclerosis. N Engl J Med. 2018; 378:169-180.
4. Ralf A. Linker, Andrew Chan. Navigating choice in multiple sclerosis management. Neurological research and practice. 2019; 1(5):2-8
5. J.H. Noseworthy et al. MULTIPLE SCLEROSIS. The new England Journal of Medicine. 2000; 343(13):938-958.
6. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother 2013; 13:3-9.
7. Compston A, Coles A. Multiple Sclerosis. Lancet. 2008; 372(9648):1502-1517.
8. NazemGhasemi, Shahnaz Razavi, ElhamNikzad. Multiple Sclerosis: Pathogenesis. Symptoms, Diagnoses and cell-based therap. Cell J. 2017; 19(1):1-10.
9. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol. 2008; 255(1):3-11.
10. Gandhi R, LaroniA, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neurol.
11. Kasper LH, Shoemaker J. Multiple Sclerosis immunology: the healthy immune system vs the MS immune system. Neurology. 2010; 74(1):2-8.
12. Brown B. Natalizumab in the treatment of multiple sclerosis. Ther.Clin. Risk Mang. 2009; 5:585-594.
13. Loma I. Heyman R. Multiple Sclerosis: Pathogenesis and treatment. Current Neuropharmacol. 2011; 9(3):409-4.
Statistics
170 Views | 45 Downloads
How to Cite
Shinde, T., Wagh, S., Solanke, K., & Folane, P. (2020). A Review on Current Treatment of Multiple Sclerosis Disease. Asian Journal of Pharmaceutical Research and Development, 8(5), 123-128. https://doi.org/https://doi.org/10.22270/ajprd.v8i5.828